Long Noncoding RNA TYKRIL Plays a Role in Pulmonary Hypertension via the p53-mediated Regulation of PDGFRβ
Christoph M Zehendner,Chanil Valasarajan,Astrid Werner,Jes-Niels Boeckel,Florian C Bischoff,David John,Tyler Weirick,Simone F Glaser,Oliver Rossbach,Nicolas Jaé,Shemsi Demolli,Fatemeh Khassafi,Ke Yuan,Vinicio A de Jesus Perez,Katharina M Michalik,Wei Chen,Werner Seeger,Andreas Guenther,Roxana M Wasnick,Shizuka Uchida,Andreas M Zeiher,Stefanie Dimmeler,Soni S Pullamsetti,Christoph M. Zehendner,Florian C. Bischoff,Simone F. Glaser,Vinicio A. de Jesus Perez,Katharina M. Michalik,Roxana M. Wasnick,Andreas M. Zeiher,Soni S. Pullamsetti
DOI: https://doi.org/10.1164/rccm.201910-2041oc
IF: 24.7
2020-11-14
American Journal of Respiratory and Critical Care Medicine
Abstract:Rationale: Long noncoding RNAs (lncRNAs) are emerging as important regulators of diverse biological functions. Their role in pulmonary arterial hypertension (PAH) remains to be explored. Objectives: To elucidate the role of TYKRIL (tyrosine kinase receptor–inducing lncRNA) as a regulator of p53/ PDGFRβ (platelet-derived growth factor receptor β) signaling pathway and to investigate its role in PAH. Methods: Pericytes and pulmonary arterial smooth muscle cells exposed to hypoxia and derived from patients with idiopathic PAH were analyzed with RNA sequencing. TYKRIL knockdown was performed in above-mentioned human primary cells and in precision-cut lung slices derived from patients with PAH. Measurements and Main Results: Using RNA sequencing data, TYKRIL was identified to be consistently upregulated in pericytes and pulmonary arterial smooth muscles cells exposed to hypoxia and derived from patients with idiopathic PAH. TYKRIL knockdown reversed the proproliferative ( n = 3) and antiapoptotic ( n = 3) phenotype induced under hypoxic and idiopathic PAH conditions. Owing to the poor species conservation of TYKRIL, ex vivo studies were performed in precision-cut lung slices from patients with PAH. Knockdown of TYKRIL in precision-cut lung slices decreased the vascular remodeling ( n = 5). The number of proliferating cell nuclear antigen–positive cells in the vessels was decreased and the number of terminal deoxynucleotide transferase–mediated dUTP nick end label–positive cells in the vessels was increased in the LNA (locked nucleic acid)-treated group compared with control. Expression of PDGFRβ, a key player in PAH, was found to strongly correlate with TYKRIL expression in the patient samples ( n = 12), and TYKRIL knockdown decreased PDGFRβ expression ( n = 3). From the transcription factor–screening array, it was observed that TYKRIL knockdown increased the p53 activity, a known repressor of PDGFRβ. RNA immunoprecipitation using various p53 mutants demonstrated that TYKRIL binds to the N-terminal of p53 (an important region for p300 interaction with p53). The proximity ligation assay revealed that TYKRIL interferes with the p53–p300 interaction ( n = 3) and regulates p53 nuclear translocation. Conclusions: TYKRIL plays an important role in PAH by regulating the p53/PDGFRβ axis.
respiratory system,critical care medicine